IDH mutational status and the immune system in gliomas: a tale of two tumors?

Transl Cancer Res. 2017 Oct;6(Suppl 7):S1253-S1256. doi: 10.21037/tcr.2017.09.37. Epub 2017 Sep 18.

Authors

Bryan D Choi¹, William T Curry¹

Affiliation

¹ Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

No abstract available

Keywords: Biomarkers; Glioma; Immunotherapy; Isocitrate Dehydrogenase.

Grants and funding

R25 NS065743/NS/NINDS NIH HHS/United States